Cargando…
Analysis of BRCA1 and RAD51C Promoter Methylation in Italian Families at High-Risk of Breast and Ovarian Cancer
Previous studies on breast and ovarian carcinoma (BC and OC) revealed constitutional BRCA1 and RAD51C promoter hypermethylation as epigenetic alterations leading to tumor predisposition. Nevertheless, the impact of epimutations at these genes is still debated. One hundred and eight women affected by...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226593/ https://www.ncbi.nlm.nih.gov/pubmed/32276467 http://dx.doi.org/10.3390/cancers12040910 |
_version_ | 1783534325072920576 |
---|---|
author | Tabano, Silvia Azzollini, Jacopo Pesenti, Chiara Lovati, Sara Costanza, Jole Fontana, Laura Peissel, Bernard Miozzo, Monica Manoukian, Siranoush |
author_facet | Tabano, Silvia Azzollini, Jacopo Pesenti, Chiara Lovati, Sara Costanza, Jole Fontana, Laura Peissel, Bernard Miozzo, Monica Manoukian, Siranoush |
author_sort | Tabano, Silvia |
collection | PubMed |
description | Previous studies on breast and ovarian carcinoma (BC and OC) revealed constitutional BRCA1 and RAD51C promoter hypermethylation as epigenetic alterations leading to tumor predisposition. Nevertheless, the impact of epimutations at these genes is still debated. One hundred and eight women affected by BC, OC, or both and considered at very high risk of carrying BRCA1 germline mutations were studied. All samples were negative for pathogenic variants or variants of uncertain significance at BRCA testing. Quantitative BRCA1 and RAD51C promoter methylation analyses were performed by Epityper mass spectrometry on peripheral blood samples and results were compared with those in controls. All the 108 analyzed cases showed methylation levels at the BRCA1/RAD51C promoter comparable with controls. Mean methylation levels (± stdev) at the BRCA1 promoter were 4.3% (± 1.4%) and 4.4% (± 1.4%) in controls and patients, respectively (p > 0.05; t-test); mean methylation levels (± stdev) at the RAD51C promoter were 4.3% (± 0.9%) and 3.7% (± 0.9%) in controls and patients, respectively (p > 0.05; t-test). Based on these observations; the analysis of constitutional methylation at promoters of these genes does not seem to substantially improve the definition of cancer risks in patients. These data support the idea that epimutations represent a very rare event in high-risk BC/OC populations. |
format | Online Article Text |
id | pubmed-7226593 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72265932020-05-18 Analysis of BRCA1 and RAD51C Promoter Methylation in Italian Families at High-Risk of Breast and Ovarian Cancer Tabano, Silvia Azzollini, Jacopo Pesenti, Chiara Lovati, Sara Costanza, Jole Fontana, Laura Peissel, Bernard Miozzo, Monica Manoukian, Siranoush Cancers (Basel) Article Previous studies on breast and ovarian carcinoma (BC and OC) revealed constitutional BRCA1 and RAD51C promoter hypermethylation as epigenetic alterations leading to tumor predisposition. Nevertheless, the impact of epimutations at these genes is still debated. One hundred and eight women affected by BC, OC, or both and considered at very high risk of carrying BRCA1 germline mutations were studied. All samples were negative for pathogenic variants or variants of uncertain significance at BRCA testing. Quantitative BRCA1 and RAD51C promoter methylation analyses were performed by Epityper mass spectrometry on peripheral blood samples and results were compared with those in controls. All the 108 analyzed cases showed methylation levels at the BRCA1/RAD51C promoter comparable with controls. Mean methylation levels (± stdev) at the BRCA1 promoter were 4.3% (± 1.4%) and 4.4% (± 1.4%) in controls and patients, respectively (p > 0.05; t-test); mean methylation levels (± stdev) at the RAD51C promoter were 4.3% (± 0.9%) and 3.7% (± 0.9%) in controls and patients, respectively (p > 0.05; t-test). Based on these observations; the analysis of constitutional methylation at promoters of these genes does not seem to substantially improve the definition of cancer risks in patients. These data support the idea that epimutations represent a very rare event in high-risk BC/OC populations. MDPI 2020-04-08 /pmc/articles/PMC7226593/ /pubmed/32276467 http://dx.doi.org/10.3390/cancers12040910 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tabano, Silvia Azzollini, Jacopo Pesenti, Chiara Lovati, Sara Costanza, Jole Fontana, Laura Peissel, Bernard Miozzo, Monica Manoukian, Siranoush Analysis of BRCA1 and RAD51C Promoter Methylation in Italian Families at High-Risk of Breast and Ovarian Cancer |
title | Analysis of BRCA1 and RAD51C Promoter Methylation in Italian Families at High-Risk of Breast and Ovarian Cancer |
title_full | Analysis of BRCA1 and RAD51C Promoter Methylation in Italian Families at High-Risk of Breast and Ovarian Cancer |
title_fullStr | Analysis of BRCA1 and RAD51C Promoter Methylation in Italian Families at High-Risk of Breast and Ovarian Cancer |
title_full_unstemmed | Analysis of BRCA1 and RAD51C Promoter Methylation in Italian Families at High-Risk of Breast and Ovarian Cancer |
title_short | Analysis of BRCA1 and RAD51C Promoter Methylation in Italian Families at High-Risk of Breast and Ovarian Cancer |
title_sort | analysis of brca1 and rad51c promoter methylation in italian families at high-risk of breast and ovarian cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226593/ https://www.ncbi.nlm.nih.gov/pubmed/32276467 http://dx.doi.org/10.3390/cancers12040910 |
work_keys_str_mv | AT tabanosilvia analysisofbrca1andrad51cpromotermethylationinitalianfamiliesathighriskofbreastandovariancancer AT azzollinijacopo analysisofbrca1andrad51cpromotermethylationinitalianfamiliesathighriskofbreastandovariancancer AT pesentichiara analysisofbrca1andrad51cpromotermethylationinitalianfamiliesathighriskofbreastandovariancancer AT lovatisara analysisofbrca1andrad51cpromotermethylationinitalianfamiliesathighriskofbreastandovariancancer AT costanzajole analysisofbrca1andrad51cpromotermethylationinitalianfamiliesathighriskofbreastandovariancancer AT fontanalaura analysisofbrca1andrad51cpromotermethylationinitalianfamiliesathighriskofbreastandovariancancer AT peisselbernard analysisofbrca1andrad51cpromotermethylationinitalianfamiliesathighriskofbreastandovariancancer AT miozzomonica analysisofbrca1andrad51cpromotermethylationinitalianfamiliesathighriskofbreastandovariancancer AT manoukiansiranoush analysisofbrca1andrad51cpromotermethylationinitalianfamiliesathighriskofbreastandovariancancer |